2022 Guidance and E.S.G. Considerations
Amedisys 2022 Preliminary Guidance
Revenue, EBITDA and EPS guidance ranges for FY 2022
($M except for EPS)
Adjusted Revenue
Adjusted
EBITDA
Adjusted EPS
AMED Core
Performance
$2,274 $2,309
-
$301-$311
$5.88 - $6.10
High Acuity Care
$56
Total
AMED
$2,330 $2,365
($26)
$275 - $285
($0.65)
2022 EBITDA Impacts:
•
.
•
Incentive Comp: ~$16M
Incremental Contessa: ~$17M
Omicron impact: ~$7M
•
De Novos: $5M
•
Investments: ~$3M
Total: $48M
Additional impact from
Contessa related to resources
needed to service expanded
Hospital @ Home JV pipeline,
along with resources allocated
to new Palliative Care business
line.
$5.23 - $5.45
Guidance Disclaimer
COVID-19 has impacted the operating metrics typically used to forecast both growth and cost assumptions for both core Amedisys and
Contessa. We are basing our guidance on our current operating environment. COVID-19 continues to evolve in both the disease itself as
well as disruptions to the healthcare systems and the economy. Any future regulations or government interventions, spike in clinicians
and BD staff on quarantine, staffing shortages due to current and proposed federal, state and local vaccine mandates, reduction in
elective procedures, change in patient behavior and further decline in senior living occupancy could impact our ability to achieve this
guidance.
17
17View entire presentation